The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir

BACKGROUND: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is currently unknown whether adding ribavirin (RBV) to SOF + SIM, which raises the pill count from two up to eight pills a day, impacts adherence. The aim of this...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinicoecon Outcomes Res
Hauptverfasser: Walker, David R, Juday, Timothy R, Manthena, Shivaji R, Jing, Yonghua, Sood, Vipan
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2015
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4687623/
https://ncbi.nlm.nih.gov/pubmed/26719716
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S87261
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge